Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Bo Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1959-1301; OpenAlex author ID A5100374401, A5109324983. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers

Papers 12

  1. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  2. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohor… Co-author DOI 10.1097/js9.0000000000000648↗
  3. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery. Co-author DOI 10.1186/s12893-023-02256-4↗
  4. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  5. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Co-author DOI 10.1097/mpa.0000000000002175↗
  6. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  7. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  8. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for… Co-author DOI 10.1016/j.surg.2020.02.013↗
  9. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Co-author DOI 10.1038/s41416-019-0704-2↗
  10. Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evalua… Co-author DOI 10.3389/fonc.2020.01472↗
  11. HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Last author DOI 10.18632/oncotarget.15266↗
  12. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. First author DOI 10.18632/oncotarget.15692↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiwei Guo · 10 shared papers, 2020–2023 · strength 1.33
  2. Gang Jin · 10 shared papers, 2020–2023 · strength 1.33
  3. Suizhi Gao · 8 shared papers, 2020–2023 · strength 0.98
  4. Guoxiao Zhang · 6 shared papers, 2021–2023 · strength 0.87
  5. Xiaohan Shi · 7 shared papers, 2020–2023 · strength 0.84
  6. Xiaoyi Yin · 5 shared papers, 2021–2023 · strength 0.77
  7. Shuo Shen · 5 shared papers, 2020–2023 · strength 0.63
  8. Kailian Zheng · 4 shared papers, 2021–2023 · strength 0.54
  9. Xiongfei Xu · 4 shared papers, 2020–2023 · strength 0.46
  10. Zhuo Shao · 3 shared papers, 2020–2023 · strength 0.34
  11. Jing Shen · 3 shared papers, 2020–2021 · strength 0.32
  12. Yang Wang · 2 shared papers, 2022–2023 · strength 0.30
  13. Lingyu Zhu · 2 shared papers, 2023 · strength 0.29
  14. Jian Wang · 2 shared papers, 2022–2023 · strength 0.29
  15. Bin Song · 1 shared paper, 2023 · strength 0.13
  16. Peng Cheng · 1 shared paper, 2023 · strength 0.13
  17. Hui Jiang · 1 shared paper, 2020 · strength 0.11
  18. Gang Li · 1 shared paper, 2021 · strength 0.10
  19. Wei Jing · 1 shared paper, 2021 · strength 0.10
  20. Fu-Rao Liu · 1 shared paper, 2017 · strength 0.07
  21. Yao Zong YUAN · 1 shared paper, 2017 · strength 0.07
  22. Pingting Zhou · 1 shared paper, 2017 · strength 0.07
  23. Yanyan Li · 1 shared paper, 2017 · strength 0.07
  24. Dong Li · 1 shared paper, 2017 · strength 0.07
  25. Xingda Wu · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.